BPC-157, also known as Body Protection Compound-157, is a synthetic peptide made up of 15 amino acids. It is derived from a naturally occurring protective protein sequence found in human gastric juice. Because of its reported effects in animal and laboratory studies, BPC-157 has been studied for tissue repair, gastrointestinal protection, tendon and ligament healing, wound healing, inflammation, and vascular repair.
BPC-157 is sometimes promoted in wellness and regenerative medicine settings for musculoskeletal injuries, gastrointestinal symptoms, recovery, and inflammation. However, most of the published evidence comes from animal and preclinical studies, not large, well-controlled human clinical trials.
BPC-157 is not FDA-approved for any medical indication in the United States. The FDA has also raised safety concerns regarding compounded BPC-157 products, including limited human safety data and concerns related to peptide impurities, aggregation, and potential immunogenicity.
The exact mechanism of action of BPC-157 has not been fully established in humans. Proposed mechanisms are based primarily on animal and laboratory studies.
Potential mechanisms include:
BPC-157 appears to have broad effects in preclinical studies, but these mechanisms remain incompletely defined and have not been fully validated in controlled human studies.
Published preclinical research suggests BPC-157 may have several biologic effects. However, most potential benefits are based on animal studies, cell-culture studies, and review articles rather than robust human clinical trials.
Potential benefits may include:
It is important to distinguish biologic plausibility from proven clinical benefit. BPC-157 has demonstrated promising regenerative and cytoprotective effects in preclinical studies, but recent reviews emphasize that well-designed human trials are still needed before it can be recommended for clinical musculoskeletal use.
Because BPC-157 is not FDA-approved and lacks large human safety trials, its full safety profile is unknown.
Potential risks may include:
The FDA has stated that compounded drugs containing BPC-157 may present safety concerns and that available information is insufficient to determine whether the drug would cause harm when administered to humans.
BPC-157 should generally be avoided or used only with extreme caution in individuals with:
Patients considering BPC-157 should be evaluated by a qualified healthcare provider, especially if they have cancer history, immune disorders, chronic inflammatory disease, impaired wound healing, diabetes, or are taking immunosuppressive medications.
BPC-157 is not FDA-approved for any medical indication in the United States.
It is not FDA-approved for:
The FDA has reviewed BPC-157 in the context of drug compounding and has identified safety concerns, including insufficient human safety data and concerns related to peptide impurities and immunogenicity.
Human Studies
Human clinical evidence for BPC-157 is limited. Unlike FDA-approved medications, BPC-157 has not been evaluated in large, high-quality randomized controlled trials for common clinical uses such as tendon injury, ligament injury, muscle recovery, joint pain, wound healing, or gastrointestinal disease.
Recent reviews describe BPC-157 as promising based on preclinical research but emphasize that available human evidence is insufficient to establish clinical safety or efficacy. A 2025 narrative review concluded that until well-designed human trials are conducted and published, BPC-157 should not be recommended for clinical use in musculoskeletal medicine.
Animal & Preclinical Studies
Most published BPC-157 research involves animal models and laboratory studies.
Animal and preclinical studies have reported that BPC-157 may:
These findings support biologic plausibility but do not prove that BPC-157 is safe or effective for the same conditions in humans.
Review Articles
Animal & Preclinical Studies
The information provided on this page is intended for educational and informational purposes only. It is not intended to diagnose, treat, cure, or prevent any disease and should not be considered medical advice.
This content was generated with the assistance of artificial intelligence (AI) and should be reviewed by a qualified medical professional before publication or clinical use. AI-generated medical content may contain errors, omissions, or outdated information.
BPC-157 is not FDA-approved for any medical indication in the United States. Its use remains investigational, and any clinical use may be considered off-label or non-approved depending on context. Individual results vary, and no specific outcome or benefit can be guaranteed. Patients should consult a qualified healthcare provider before beginning or changing any medical treatment.
R2 Medical Clinic uses medications sourced from compounding pharmacies. Compounded medications are not approved by the U.S. Food and Drug Administration (FDA). Unlike FDA-approved medications, compounded drugs have not undergone FDA review for safety, effectiveness, or efficacy through the FDA drug approval process. While 503B outsourcing facilities are registered with and inspected by the FDA and must comply with Current Good Manufacturing Practice (CGMP) requirements, the compounded medications they produce are not individually approved by the FDA. Similarly, compounded medications prepared by 503A pharmacies are not FDA-approved and are primarily regulated by state boards of pharmacy, with FDA oversight under applicable federal law.
# KPV